However in another study, treatment with GW501516, a PPARβ/δ agonist, enhanced prostaglandin E receptor 4 (EP4) expression and promoted NSCLC proliferation, demonstrating that PPARβ/δ activation may be a unique molecular strategy to control the development of human cancer [157]. This evidence concerns the gene PTGER4 and cancer.